- cafead   Sep 27, 2022 at 10:32: AM
via Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart.
article source
article source